Chelsea McLean | Clinical Science Director
Johnson & Johnson Innovative Medicines

I am currently Clinical Science Director at Johnson & Johnson, where I am accountable for clinical efficacy and immunogenicity data for the global ExPEC vaccine program. Prior to that, I was the Compound Development Team Lead for the Johnson & Johnson Global Universal Flu vaccine, and the Senior Biomarker Lead for the Johnson & Johnson Global Ebola vaccine program where I contributed to successful licensure of the vaccine in 8 countries in Africa. After completing my Bachelor of Science Degree in Microbiology and Molecular Genetics at Michigan State University, I obtained a Ph.D. in Genetics and Development from Cornell University.  My first post-doctoral position was at the University of Oxford, performing whole-genome sequencing to identify mutations associated with muscle-invasive bladder cancer. This was followed by additional post-doctoral work at the Netherlands Cancer Institute in Amsterdam, where I used transcriptomic, genomic, and organoid techniques to investigate thymic lymphoma, colorectal cancer, and hereditary gastric cancer.  It was my experience with ‘omics analyses that not only lead to my first position with Johnson & Johnson, focused on lung cancer, but also facilitated my transition from oncology to vaccine clinical development, as I also headed the Johnson & Johnson Viral Vaccines ‘Omics Analysis Team.